Answers are grounded in this paper and cite their sources.
Observational study evaluates liver toxicity indicators in patients with inflammatory rheumatism, suggesting improved monitoring strategies.
Background/Aims Methotrexate (MTX) is a standard treatment for chronic inflammatory rheumatism. However, prolonged use can cause liver damage, ranging from simple cytolysis to fibrosis. Assessing these adverse effects is particularly important in patients with metabolic risk factors. To evaluate the impact of MTX on the liver in patients being treated for inflammatory rheumatism by analyzing liver function tests, FIB-4 scores, FibroScan results in patients at risk, and factors associated with liver toxicity. Methods We conducted a retrospective study in the rheumatology department at University Hospital from January 2021 to March 2025, including patients being treated for chronic inflammatory rheumatism with methotrexate who had experienced a hepatic side effect, particularly cytolysis. Demographic, clinical, biological, and therapeutic data were extracted from computerized records. The FIB-4 score was calculated for all patients, and a FibroScan was performed in those with risk factors for liver disease. The results were analyzed and summarized using Excel. Results Of the 680 cases reviewed, 30 patients were included. The average age was 53.4 ± 11.2 years, with a predominance of women (93.3%). Among them, 33.3% were overweight and 23.3% had dyslipidemia. The majority of patients were being treated for seropositive rheumatoid arthritis (90%), while the others were being treated for psoriatic arthritis (10%). The mean duration of MTX exposure was 6.4 ± 6.3 years, with a mean weekly dose of 16.8 ± 6.5 mg and a mean cumulative dose of 5.1 ± 5.3 g. The mean FIB-4 fibrosis score was 1.66 ± 0.93. Statistical analysis showed no significant association between advanced fibrosis (F3/F4) and cumulative MTX dose (p = 0.225), duration of exposure (p = 0.667), or weekly dose (p = 0.412). Conclusion Our study confirms that the risk of liver damage under MTX remains low in the absence of associated steatosis. These data suggest that monitoring recommendations should be re-evaluated in light of recent knowledge and that the management of metabolic risk factors should be optimized. An approach combining liver function tests, FIB-4, FibroScan, and risk factor management allows for safer and more optimal use of methotrexate.
No takes yet. Share an insight, caveat, or question.
Maghfour et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: